- Report
- August 2026
- 172 Pages
Global
From €5180EUR$5,850USD£4,439GBP
- Report
- June 2026
- 200 Pages
Global
From €2648EUR$2,990USD£2,269GBP
- Report
- January 2026
- 184 Pages
Global
From €3139EUR$3,545USD£2,690GBP
€3488EUR$3,939USD£2,989GBP
- Report
- January 2026
- 185 Pages
Global
From €3139EUR$3,545USD£2,690GBP
€3488EUR$3,939USD£2,989GBP
- Report
- February 2026
- 250 Pages
Global
From €3976EUR$4,490USD£3,407GBP
- Report
- February 2026
- 250 Pages
Global
From €3976EUR$4,490USD£3,407GBP
- Drug Pipelines
- April 2026
- 80 Pages
Global
From €1771EUR$2,000USD£1,517GBP
- Report
- August 2026
- 136 Pages
Global
From €4206EUR$4,750USD£3,604GBP
- Report
- April 2026
- 142 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Clinical Trials
- January 2026
- 192 Pages
Global
From €3055EUR$3,450USD£2,618GBP
- Report
- January 2026
- 145 Pages
Global
From €3498EUR$3,950USD£2,997GBP
- Report
- August 2026
- 184 Pages
Global
From €3139EUR$3,545USD£2,690GBP
€3488EUR$3,939USD£2,989GBP
- Report
- June 2026
- 326 Pages
Global
From €2214EUR$2,500USD£1,897GBP
- Report
- September 2025
- 120 Pages
Middle East
From €5269EUR$5,950USD£4,515GBP
- Report
- July 2025
- 200 Pages
United States
From €2205EUR$2,490USD£1,889GBP
- Report
- September 2023
- 170 Pages
Global
From €1762EUR$1,990USD£1,510GBP
- Report
- August 2025
- 120 Pages
United States
From €5269EUR$5,950USD£4,515GBP
- Report
- June 2025
- 120 Pages
Global
From €5269EUR$5,950USD£4,515GBP
- Report
- May 2025
- 150 Pages
Global
From €5269EUR$5,950USD£4,515GBP
- Report
- August 2025
- 184 Pages
Global
From €3139EUR$3,545USD£2,690GBP
€3488EUR$3,939USD£2,989GBP

The Huntington Disease Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs used to treat Huntington Disease, a rare, inherited neurological disorder that causes the progressive breakdown of nerve cells in the brain. Symptoms of the disease include involuntary movements, cognitive decline, and psychiatric disturbances. Currently, there is no cure for Huntington Disease, but medications can help manage symptoms and slow the progression of the disease.
The Huntington Disease Drug market is composed of both branded and generic drugs. Branded drugs are typically more expensive than generic drugs, but they may offer more effective symptom management. The market is highly competitive, with many companies vying for market share.
Some companies in the Huntington Disease Drug market include AbbVie, Teva Pharmaceuticals, and Lundbeck. Show Less Read more